Recruiting PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT06319235

Clinical Trial to Demonstrate the Safety and Efficacy of DUOFAG®

A Prospective, Randomized, Double-blind, Placebo-controlled Phase I/IIa Clinical Trial to Demonstrate the Safety and Efficacy of DUOFAG® in Bacterial Infection Treatment in Patients With Surgical Wounds

Sponsor: MB PHARMA s.r.o.

Conditions Bacterial Infections Pseudomonas Aeruginosa Infection Staphylococcus Aureus Infection Surgical Site Infection Surgical Wound Infection

Interventions IMP Placebo

Updated 3 times since 2024 Last updated: Mar 13, 2024 Started: Oct 27, 2023 Primary completion: Dec 31, 2025 Completion: Dec 31, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06319235, this PHASE1/PHASE2 trial focuses on Bacterial Infections and Pseudomonas Aeruginosa Infection and remains actively recruiting participants. Sponsored by MB PHARMA s.r.o., it has been updated 3 times since 2023, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

3 versions recorded

Sep 2024 — Present [monthly]

Recruiting PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Apr 2024 — Jul 2024 [monthly]

Recruiting PHASE1_PHASE2

First recorded

Oct 2023

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

MB PHARMA s.r.o.

Data source: MB PHARMA s.r.o.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Brno, Czechia